CLDX — CELLDEX THERAPEUTICS INC NEW

Ownership history in Eversept Partners, LP  ·  19 quarters on record

This page tracks every 13F SEC filing in which Eversept Partners, LP reported a position in CELLDEX THERAPEUTICS INC NEW (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.76% (2023 Q2)
Avg. % of fund
1.8%
First filed
2020 Q2
Last filed
2025 Q4
Quarters held
19
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 1,434,725 +280,805 +24.3% 1.96% $39.0M $27.16
2025 Q3 ADDED 1,153,920 +315,184 +37.6% 2.06% $29.9M $25.87
2025 Q2 ADDED 838,736 +142,237 +20.4% 1.57% $17.1M $20.35
2025 Q1 REDUCED 696,499 -23,337 -3.2% 1.28% $12.6M $18.15
15 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CLDX price (monthly, adj. close)

Other funds also holding CLDX

As of 2025 Q4 — sorted by position size

Kynam Capital Management, LP 3Y 10.31% Elmind Capital, LP 6.93% Commodore Capital LP 3Y 4.64% 5AM Venture Management, LLC 3Y 4.25% Propel Bio Management, LLC 3.58% GordonMD Global Investments LP 3.32% Novo Holdings A/S 3Y 7Y 2.53% TSP Capital Management Group, LLC 3Y 7Y 2.49% Bellevue Group AG 3Y 7Y 1.86% BRAIDWELL LP 3Y 1.61%
← Back to Eversept Partners, LP Holdings